| Primary information |
|---|
| ID | antitb_1272, |
| Name | 25759383 |
| N-Terminal modification | Inhibitor 2 |
| C-Terminal Modification | HK-(boroMet) |
| Chemical Modification | Acetylation |
| Linear/Cyclic | Free |
| Length | boroMet = methionine boronic acid |
| Chirality | Linear |
| Nature | 3 |
| Source | L |
| Species | Synthetic |
| Strain | substrate-based boronate inhibitors |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC50 = 6 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2015 |
| Cytotoxicity | Myeloma cells (MM1.S) |
| In vivo Model | NA |
| Lethal Dose | No cytotoxicty |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. |
| Other activities | ClpP1P2 peptidase |
| PMID | None |
| Year of Publication | None |
Tertiary Structure
(Technique) | Not Predicted), |